Stockscreener 앱 받기
5.47
3.36%
-0.19
Solid Biosciences Inc 주식(SLDB)의 최신 뉴스
Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient - NeurologyLive
Solid Biosciences director Ilan Ganot sells $447 in stock - MSN
Solid Bio rises as Duchenne study gets fully enrolled - MSN
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success - Pharmaceutical Technology
FOMO Trade: Does Solid Biosciences Inc offer margin of safetyQuarterly Profit Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Solid Biosciences (SLDB) Completes Enrollment in Key Duchenne St - GuruFocus
Needham Reiterates Buy Rating on SLDB with Price Target of $16.0 - GuruFocus
Needham & Company LLC Reiterates "Buy" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Bio fully enrolls Duchenne study for lead drug (SLDB) - Seeking Alpha
Solid Biosciences advances gene therapy trials for rare diseases By Investing.com - Investing.com Nigeria
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial - Intellectia AI
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 5,704 Shares - MarketBeat
Solid Biosciences advances gene therapy trials for rare diseases - Investing.com
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 - The Manila Times
Rare disease gene trials grow as Solid Biosciences inks 50+ capsid pacts - Stock Titan
Solid Biosciences doses first participant in Friedreich’s ataxia trial By Investing.com - Investing.com Nigeria
Solid Biosciences receives FDA orphan drug designation for FA therapy By Investing.com - Investing.com Nigeria
Solid Biosciences Gets Orphan Drug Label for SGT-212 to Treat Friedreich's Ataxia - marketscreener.com
SLDB Gains FDA Orphan Drug Designation for SGT-212 in Treating F - GuruFocus
Solid Biosciences receives FDA orphan drug designation for FA therapy - Investing.com
Solid Biosciences Announces FDA Designations for SGT-212 and Completion of First Dosing in Phase 1b FALCON Trial for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences receives FDA orphan drug designation for SGT-212 dual-route gene therapy - marketscreener.com
Solid Biosciences Receives FDA Orphan Drug Designation for - GlobeNewswire
Solid Biosciences (SLDB) Begins Dosing in FALCON Trial for SGT-2 - GuruFocus
Solid Biosciences doses first participant in Friedreich’s ataxia trial - Investing.com
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia - The Manila Times
Solid Biosciences Doses First Participant in First-In-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia - marketscreener.com
Can Solid Biosciences Inc. stock rebound after recent weaknessWeekly Trading Summary & Real-Time Price Movement Reports - Улправда
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Solid Biosciences (NASDAQ:SLDB) Shares Down 2.2%Here's What Happened - MarketBeat
Solid Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why one new Solid Biosciences hire is getting 7,000 stock units - Stock Titan
Published on: 2026-01-01 04:47:43 - moha.gov.vn
Aug Reactions: Is Solid Biosciences Inc stock a buy before product launches2025 AllTime Highs & Risk Controlled Stock Pick Alerts - moha.gov.vn
Is Solid Biosciences Inc. stock a buy before product launchesJuly 2025 Setups & Smart Investment Allocation Tips - DonanımHaber
Cartography Biosciences’ CBI-1214 gains IND clearance - BioWorld MedTech
Update Report: Is Solid Biosciences Inc. stock a bargain at current levels2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
Solid Biosciences stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
Gene Therapy Milestones And Collaborations Keep Solid Biosciences In Focus - RTTNews
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services - The Manila Times
Solid Biosciences (SLDB) Sees Duchenne Screening Advancement in US - GuruFocus
Solid Biosciences stock rises after Duchenne added to newborn screening list - Investing.com
Solid Biosciences Supports Duchenne Muscular Dystrophy Inclusion in U.S. Newborn Screening Recommendations - Quiver Quantitative
U.S. newborns will now be screened for Duchenne muscular dystrophy - Stock Titan
Solid Biosciences (SLDB) Gains Attention with Duchenne Muscular Dystrophy Inclusion - GuruFocus
Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy - Finviz
Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy - Insider Monkey
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum - GlobeNewswire
Bollard Group LLC Acquires New Holdings in Solid Biosciences Inc. $SLDB - MarketBeat
Needham & Company LLC Upgrades Solid Biosciences (NASDAQ:SLDB) to Moderate Buy - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):